148 related articles for article (PubMed ID: 28114374)
1. P-mTOR Expression and Implication in Breast Carcinoma: A Systematic Review and Meta-Analysis.
Ding XF; Li LF; Zhou XL; Guo LN; Dou MM; Chi YY; Wu SX; Zhang YN; Shan ZZ; Zhang YJ; Wang F; Fan QX; Zhao J; Sun TW
PLoS One; 2017; 12(1):e0170302. PubMed ID: 28114374
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysis.
Li S; Wang Z; Huang J; Cheng S; Du H; Che G; Peng Y
BMC Cancer; 2016 Nov; 16(1):877. PubMed ID: 27835987
[TBL] [Abstract][Full Text] [Related]
3. mTOR pathway protein immunoexpression as a prognostic factor for survival in head and neck cancer patients: a systematic review and meta-analysis.
Marques AE; Elias ST; Porporatti AL; Castilho RM; Squarize CH; De Luca Canto G; Guerra EN
J Oral Pathol Med; 2016 May; 45(5):319-28. PubMed ID: 26661562
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of MMP Family Members Functions as Prognostic Biomarker for Breast Cancer Patients: A Systematic Review and Meta-Analysis.
Ren F; Tang R; Zhang X; Madushi WM; Luo D; Dang Y; Li Z; Wei K; Chen G
PLoS One; 2015; 10(8):e0135544. PubMed ID: 26270045
[TBL] [Abstract][Full Text] [Related]
5. p-mTOR expression is associated with better prognosis in luminal breast carcinoma.
Beca F; Andre R; Martins DS; Bilhim T; Martins D; Schmitt F
J Clin Pathol; 2014 Nov; 67(11):961-7. PubMed ID: 25053543
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylated Mammalian Target of Rapamycin p-mTOR Is a Favorable Prognostic Factor than mTOR in Gastric Cancer.
Cao GD; Xu XY; Zhang JW; Chen B; Xiong MM
PLoS One; 2016; 11(12):e0168085. PubMed ID: 28005970
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of matrix metalloproteinase 9 expression in breast cancer patients: a meta-analysis.
Song J; Su H; Zhou YY; Guo LL
Asian Pac J Cancer Prev; 2013; 14(3):1615-21. PubMed ID: 23679245
[TBL] [Abstract][Full Text] [Related]
8. The prognostic role of mTOR and p-mTOR for survival in non-small cell lung cancer: a systematic review and meta-analysis.
Li L; Liu D; Qiu ZX; Zhao S; Zhang L; Li WM
PLoS One; 2015; 10(2):e0116771. PubMed ID: 25680114
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of survivin in breast cancer: meta-analysis.
Li Y; Ma X; Wu X; Liu X; Liu L
Breast J; 2014; 20(5):514-24. PubMed ID: 25041354
[TBL] [Abstract][Full Text] [Related]
10. [P27Kip1 expression and its prognostic implication in breast carcinoma: a meta-analysis].
Xie RL; Guan XX; Chen LB; Wang JH; Bai JL; Zhu BL; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2008 Feb; 37(2):92-8. PubMed ID: 18681319
[TBL] [Abstract][Full Text] [Related]
11. Survival and disease-free benefits with mastectomy versus breast conservation therapy for early breast cancer: a meta-analysis.
Chen Y; Jiang L; Gao B; Cheng ZY; Jin J; Yang KH
Breast Cancer Res Treat; 2016 Jun; 157(3):517-25. PubMed ID: 27246814
[TBL] [Abstract][Full Text] [Related]
12. A meta-analysis of randomized controlled trials comparing the efficacy and safety of anastrozole versus tamoxifen for breast cancer.
Yang Y; Pan W; Tang X; Wu S; Sun X
Oncotarget; 2017 Jul; 8(29):48362-48374. PubMed ID: 28415634
[TBL] [Abstract][Full Text] [Related]
13. mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials.
Rotundo MS; Galeano T; Tassone P; Tagliaferri P
Oncotarget; 2016 May; 7(19):27055-66. PubMed ID: 26895472
[TBL] [Abstract][Full Text] [Related]
14. The association between the methylation frequency of BRCA1/2 gene promoter and occurrence and prognosis of breast carcinoma: A meta-analysis.
Li S; He Y; Li C; Liu X; Shen Y; Wu Y; Bai N; Li Q
Medicine (Baltimore); 2020 Mar; 99(10):e19345. PubMed ID: 32150073
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
16. Impact of estrogen receptor-β expression on breast cancer prognosis: a meta-analysis.
Liu J; Guo H; Mao K; Zhang K; Deng H; Liu Q
Breast Cancer Res Treat; 2016 Feb; 156(1):149-62. PubMed ID: 26902609
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of microRNAs in cervical carcinoma: a systematic review and meta-analysis.
Dai S; Lu Y; Long Y; Lai Y; Du P; Ding N; Yao D
Oncotarget; 2016 Jun; 7(23):35369-78. PubMed ID: 27177085
[TBL] [Abstract][Full Text] [Related]
18. The impact of chemokine receptor CXCR4 on breast cancer prognosis: a meta-analysis.
Xu TP; Shen H; Liu LX; Shu YQ
Cancer Epidemiol; 2013 Oct; 37(5):725-31. PubMed ID: 23763828
[TBL] [Abstract][Full Text] [Related]
19. [HER2 expression and its prognostic implication in lymph node negative breast carcinoma: a Meta-analysis].
Guo H; Wei B; Zhang HY; Liu GJ; Bu H; Lang ZQ; Tang X; Dai QQ; Chen HJ; Zhou Y
Zhonghua Bing Li Xue Za Zhi; 2005 Mar; 34(3):140-6. PubMed ID: 15938823
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients.
Petrelli F; Viale G; Cabiddu M; Barni S
Breast Cancer Res Treat; 2015 Oct; 153(3):477-91. PubMed ID: 26341751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
